Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etoricoxib/tizanidine - Merck Sharp & Dohme

Drug Profile

Etoricoxib/tizanidine - Merck Sharp & Dohme

Alternative Names: Etoricoxib/tizanidine MR; Immediate-release etoricoxib/modified-release tizanidine - Merck; MK-0663B; Tizanidine/etoricoxib

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antirheumatics; Antispastics; Imidazolines; Muscle relaxants; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Musculoskeletal pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-pain in USA (PO, Tablet)
  • 01 Apr 2015 Merck terminates a phase III trial for Back pain in USA prior to enrolment (NCT01979510)
  • 08 Nov 2013 Merck plans a phase III trial for Back pain in USA (NCT01979510)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top